CardioSomaticsCardioSomaticsCardioСоматика2221-71852658-5707Eco-Vector4533610.26442/CS45336ArticlesСтатьиReview ArticleTreatment of atherogenic dyslipidemia: modern principles and new possibilitiesЛечение атерогенных дислипидемий: современные принципы и новые возможностиBubnovaM. GБубноваМ. Г

д-р мед. наук, проф., рук. отд. реабилитации и вторичной профилактики сочетанной патологии с лаб. профилактики атеросклероза и тромбоза ФГБУ НМИЦ ПМ

mbubnova@gnicpm.ruNational Medical Center for Preventive Medicine of the Ministry of Health of the Russian FederationФГБУ «Национальный медицинский исследовательский центр профилактической медицины» Минздрава России1506201782VOL 8, NO2 (2017)ТОМ 8, №2 (2017)515824092020Copyright ©; 2017, Eco-VectorCopyright ©; 2017, ООО "Эко-Вектор"2017Eco-VectorООО "Эко-Вектор"https://creativecommons.org/licenses/by-nc-sa/4.0https://cardiosomatics.ru/2221-7185/article/view/45336

The review presents the main provisions of the current recommendations of the European and American communities on the diagnosis and treatment of atherogenic dyslipidemia. Evidence of the importance of reducing the level of low-density lipoprotein cholesterol as a key factor in the development of cardiovascular diseases caused by atherosclerosis and the primary goal of lipid lowering therapy are given. Unresolved problems of statin therapy are indicated. A characteristic of a new class of lipid-lowering drugs is the inhibitors of the subtilisin/kexin type 9 proprotein convertase (PCSK9). The results of the first large studies with the PCSK9 inhibitor evoloucumab were discussed, which allowed to formulate the main indications for the prescriftion of this group of drugs in clinical practice.

В обзоре представлены основные положения современных рекомендаций европейских и американских сообществ по диагностике и лечению атерогенных дислипидемий. Приведены доказательства важности снижения уровня холестерина липопротеидов низкой плотности как ключевого фактора развития сердечно-сосудистых заболеваний, обусловленных атеросклерозом, и первичной цели гиполипидемической терапии. Обозначены нерешенные проблемы терапии статинами. Представлена характеристика нового класса гиполипидемических препаратов - ингибиторов пропротеин конвертазы субтилизин/кексин типа 9 (PCSK9). Обсуждены результаты первых крупных исследований с ингибитором PCSK9 эволокумабом, позволившие сформулировать основные показания к назначению этой группы препаратов в клинической практике.

cardiovascular risklipid-lowering therapystatinsinhibitors of subtilisin/kexin-type proprotein convertase 9evolocumabсердечно-сосудистый рискгиполипидемическая терапиястатиныингибиторы пропротеин конвертазы субтилизин/кексин типа 9эволокумабFerence B.A, Ginsberg H.N, Graham I et al. Low - density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J 2017. DOI: 10.1093/eurheartj/ehx144Jacobson T.A, Ito M.K, Maki K.C et al. National Lipid Association Recommendations for Patient - Centered Management of Dyslipidemia: Part 1 - Full Report. J Clin Lipidol 2015; 9: 129-69.Keys A, Menotti A, Aravanis C et al. Seven Countries Study. The seven countries study: 2,289 deaths in 15 years. Prev Med 1984; 13 (2): 141-54.Piepoli M.F, Hoes A.W, Agewall S et al; Authors/Task Force Members. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: the Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts): developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J 2016; 37: 2315-81.Catapano A.L, Graham I, De Backer G et al. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). Eur Heart J 2016; 37: 2999-3058. DOI: 10.1093/ eurheartj/ehw272Stone N.J, Robinson J, Lichtenstein A.H et al. 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014; 63: 2889-934.Lloyd-Jones D.M, Morris P.В, Ballantyne C.M et al. 2016 ACC Expert Consensus Decision Pathway on the Role of Non - Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk J Am Coll Cardiol 2016; 68: 92-125.Cholesterol Treatment Trialists’ (CTT) Collaboration, Baigent C, Blackwell L, Emberson J et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta - analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010; 376: 1670-81.Holmes M.V, Asselbergs F.W, Palmer T.M et al; UCLEB Consortium. Mendelian randomization of blood lipids for coronary heart disease. Eur Heart J 2015; 36: 539-50.Ference B.A, Yoo W, Alesh I et al. Effect of long - term exposure to lower low - density lipoprotein cholesterol beginning early in life on the risk of coronary heart disease: a Mendelian randomization analysis. J Am Coll Cardiol 2012; 60: 2631-9.Silverman M.G, Ference B.A, Im K et al. Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: a systematic review and meta - analysis. JAMA 2016; 316: 1289-97.Collins R, Reith C, Emberson J et al. Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet 2016; 388: 2532-61.Nissen S.E, Nicholls S.J, Sipahi I et al. ASTEROID Investigators. Effect of very high - intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA 2006; 295:1556-65.Nicholls S.J, Ballantyne C.M, Barter P.J et al. Effect of two intensive statin regimens on progression of coronary disease. N Engl J Med 2011; 365: 2078-87.Townsend N, Nichols M, Scarborough P, Rayner M. Cardiovascular disease in Europe - epidemiological update 2015. Eur Heart J 2015; 36: 2696-705.Mc Guinnes B, O’Hare J, Craig D. et al. Cochrane review on 'Statins for the treatment of dementia'. Int J Geriatr Psychiatry 2013; 28 (2): 119-26.Mc Kinney J.S., Kostis W.J. Statin therapy and the risk of intracerebral hemorrhage: a metaanalysis of 31 randomized controlled trials. Stroke 2012; 43 (8): 2149-56.Cai X, Tian Y, Wu T. et al. The role of statins in erectile dysfunction: a systematic review and meta - analysis. Asian J Androl 2014; 16 (3): 461-6.Kotseva K, Wood D, De Bacquer D et al, on behalf of the EUROASPIRE Investigators. EUROASPIRE IV: a European Society of Cardiology survey on the lifestyle, risk factor and therapeutic management of coronary patients from 24 European countries. Eur J Prev Cardiol 2016; 23 (6): 636-48.Оганов Р.Г., Кухарчук В.В., Арутюнов Г.П. и др. Сохраняющиеся нарушения показателей липидного спектра у пациентов с дислипидемией, получающих статины, в реальной клинической практике в Российской Федерации (российская часть исследования DYSIS). Кардиоваск. терапия и профилактика. 2012; 4: 70-8.Goldstein J.L, Brown M.S. A century of cholesterol and coronaries: from plaques to genes to statins. Cell 2015; 161: 161-72.Graham J.H, Sanchez R.J, Saseen J.J et al. Clinical and economic consequences of statin intolerance in the United States: Results from an integrated health system. J Clin Lipidol 2017; 11: 70-9. http://dx.doi.org/10.1016/j.jacl.2016.10.003Chodick G, Shalev V, Gerber Y et al. Longterm persistence with statin treatment in a not - for - profit health maintenance organization: a population - based retrospective cohort study in Israel. Clin Ther 2008; 30: 2167-79.Law M, Rudnicka A.R. Statin safety: a systematic review. Am J Cardiol 2006; 97: 52C-60C.Rosenson R.S, Baker S.K, Jacobson T.A et al. The National Lipid Association’s Muscle Safety Expert P. An assessment by the Statin Muscle Safety Task Force: 2014 update. J Clin Lipidol 2014; 8: S58-S71.Abifadel M, Varret M, Rabes J.P et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet 2003; 34: 154-6.Abifadel M, Varret M, Rabee J.D et al. Mutations in PCSK9 cause autosomal PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med 2006; 354: 1264-7.Saavedra Y.G, Dufour R, Davignon J, Baass A. PCSK9 R46L, lower LDL, and cardiovascular disease risk in familial hypercholesterolemia: a cross - sectional cohort study. Arterioscler Thromb Vasc Biol 2014; 34: 2700-5.Cohen J.C, Boerwinkle E, Mosley T.H Jr, Hobbs H.H. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med 2006; 354: 1264-72.Urban D, Pöss J, Böhm M, Laufs U. Targetting the proprotein convertase subtisilin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis. J Am Coll Cardiol 2013; 62: 1401-8.Rashid S, Curtis D.E, Garuti R et al. Decreased plasma cholesterol and hypersensitivity to statins in mice lacking PCSK9. Proc Natl Acad Sci USA 2005; 102: 5374-9.Kwakernaak A.J, Lambert G, Dullaart R.P. Plasma proprotein convertase subtilisin - kexin type 9 is predominantly related to intermediate density lipoproteins. Clin Biochem 2014; 47: 679-82.Sullivan S, Fabbrini E, Horton J.D et al. Lack of a relationship between plasma PCSK9 concentrations and hepatic lipoprotein kinetics in obese people. Transl Res 2011; 158: 302-6.Le May C, Kourimate S, Langhi C et al. Proprotein convertase subtilisin kexin type 9 null mice are protected from postprandial triglyceridemia. Arterioscler Thromb Vasc Biol 2009; 29: 684-90.Robinson J.G, Nedergaard B.S, Rogers W.J, et al. Effect of evolocumab or ezetimibe added to moderate - or high - intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial. JAMA 2014; 311: 1870-82.Koren M.J, Sabatine M.S, Giugliano R.P et al. Long - term Low - Density Lipoprotein Cholesterol - Lowering Efficacy, Persistence, and Safety of Evolocumab in Treatment of Hypercholesterolemia Results Up to 4 Years From the Open - Label OSLER-1. Extension Study JAMA Cardiol 2017. DOI: 10.1001/jamacardio.2017.0747Sabatine M.S, Giugliano R.P, Keech A.C et al. FOURIER Steering Committee and Investigators. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl J Med 2017; 376: 1713-22. DOI: 10.1056/NEJMoa1615664Nicholls S.J, Puri R, Anderson T et al. Effect of evolocumab on progression of coronary disease in statin - treated patients. The GLAGOV randomized clinical trial. JAMA 2016; 316: 2373-84.Gugliano R.P, Mach F, Zavitz K et al. Primary results of EBBINGHAUS, a cognitive study of patients enrolled in the FOURIER trial. American College of Cardiology 2017 Scientific Sessions; March 18, 2017; Washington DC. Abstract 17-LB-16161-AC.Landmesser U, Chapman M.J, Farnier M et al. European Society of Cardiology (ESC)/European Atherosclerosis Society (EAS) Task Force consensus statement on proprotein convertase subtilisin/kexin type 9 inhibitors: practical guidance for use in patients at very high cardiovascular risk. Eur Heart J 2016. pii: ehw480.Orringer C.E, Jacobson T.A, Saseen J.J et al. Update on the use of PCSK9 inhibitors in adults: Recommendations from an Expert Panel of the National Lipid Association. J Clin Lipidol 2017. http://creativecommons.org/licenses/by-nc-nd/4.0/ http://dx.doi.org/10.1016/j.jacl.2017. 05.001.Бойцов С.А., Карпов Ю.А., Ежов М.В. и др. Результаты клинического исследования FOURIER, новые возможности лечения пациентов очень высокого сердечно - сосудистого риска. Рос. кардиол. журн. 2017; 5: 85-90.Descamps O.S, Bruniaux M, Guilmot P.F et al. Lipoprotein concentrations in newborns are associated with allelic variations in their mothers. Atherosclerosis 2004; 172: 287-98.Chapman M.J. Animal lipoproteins: chemistry, structure, and comparative aspects. J Lipid Res 1980; 21: 789-853.